MedPath

Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery

Not Applicable
Conditions
Cardiac Surgery
Interventions
Drug: Intravenous Crystalloid
Registration Number
NCT02757118
Lead Sponsor
Konkuk University Medical Center
Brief Summary

After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing cardiac surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15).

All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number). After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department.

According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture.

Patient data and statistical analyses:

Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge.

All statistical analyses will be performed after the 30th patient's discharge and data acquisition

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients undergoing coiling embolization procedure due to cardiac surgery
  • Patients provided a written informed consent.
  • Patients with preoperative serum hemoglobin concentration >13 g/dL (male) and >12 g/dL (female)
  • Patients with PaO2/FiO2 ratio >150
Exclusion Criteria
  • Patients with history of anemia, dyspnea, active infection.
  • Patients with endocrine disease
  • Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-platelet drug, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing cardiac surgery.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intravenous CrystalloidIntravenous Crystalloidcrystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Intravenous HESIntravenous HESHES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Primary Outcome Measures
NameTimeMethod
whole blood viscositywith 1 hour after the completion of procedure
Secondary Outcome Measures
NameTimeMethod
hematocritwith 1 hour after the completion of procedure

serum hematocrit, %

PaO2/FiO2 ratiowith 1 hour after the completion of procedure

PaO2/FiO2 ratio measured by arterial blood gas analysis

glucosewith 1 hour after the completion of procedure

serum glucose level, g/dl

osmolaritywith 1 hour after the completion of procedure

serum osmolarity, mOsm

urine outputwith 1 hour after the completion of procedure

hourly urine output, ml/hr

Maximum clot formationwith 1 hour after the completion of procedure

Maximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm

© Copyright 2025. All Rights Reserved by MedPath